scholarly journals Adverse Health Effects of Chronic Exposure to Low-Level Cadmium in Foodstuffs and Cigarette Smoke

2004 ◽  
Vol 112 (10) ◽  
pp. 1099-1103 ◽  
Author(s):  
Soisungwan Satarug ◽  
Michael R. Moore
Keyword(s):  
Health Effects ◽  
Cigarette Smoke ◽  
Chronic Exposure ◽  
Low Level ◽  
Adverse Health Effects ◽  
Adverse Health

Cigarette smoke extract may induce lysosomal storage disease-like adverse health effects

2018 ◽  
Vol 39 (3) ◽  
pp. 510-524 ◽  
Author(s):  
Eun-Jung Park ◽  
Yoo-Jin Park ◽  
Sang Jin Lee ◽  
Cheolho Yoon ◽  
Kyuhong Lee
Keyword(s):  
Health Effects ◽  
Cigarette Smoke ◽  
Lysosomal Storage Disease ◽  
Storage Disease ◽  
Cigarette Smoke Extract ◽  
Lysosomal Storage ◽  
Adverse Health Effects ◽  
Adverse Health

scholarly journals Prolonged exposure to arsenic in UK private water supplies: toenail, hair and drinking water concentrations

2016 ◽  
Vol 18 (5) ◽  
pp. 562-574 ◽  
Author(s):  
D. R. S. Middleton ◽  
M. J. Watts ◽  
E. M. Hamilton ◽  
T. Fletcher ◽  
G. S. Leonardi ◽  
...  
Keyword(s):  
Drinking Water ◽  
Health Effects ◽  
Chronic Exposure ◽  
Prolonged Exposure ◽  
Water Supplies ◽  
Adverse Health Effects ◽  
Adverse Health

Chronic exposure to arsenic (As) in drinking water is an established cause of cancer and other adverse health effects.

scholarly journals Cigarette smoke and adverse health effects: An overview of research trends and future needs

2007 ◽  
Vol 16 (03) ◽  
pp. 77-83 ◽  
Author(s):  
Sibu P Saha ◽  
Deepak K Bhalla ◽  
Thomas F Whayne ◽  
CG Gairola
Keyword(s):  
Health Effects ◽  
Cigarette Smoke ◽  
Research Trends ◽  
Adverse Health Effects ◽  
Adverse Health ◽  
Future Needs

scholarly journals Study protocol for a randomised controlled trial examining the effect of blood and plasma donation on serum perfluoroalkyl and polyfluoroalkyl substance (PFAS) levels in firefighters

BMJ Open ◽  
2021 ◽  
Vol 11 (5) ◽  
pp. e044833
Author(s):  
Gabriel Silver ◽  
Yordanka Krastev ◽  
Miriam K Forbes ◽  
Brenton Hamdorf ◽  
Barry Lewis ◽  
...  
Keyword(s):  
Randomised Controlled Trial ◽  
Health Effects ◽  
Whole Blood ◽  
Sulfonic Acid ◽  
Controlled Trial ◽  
Adverse Health Effects ◽  
Plasma Donation ◽  
Adverse Health ◽  
Study Results ◽  
Randomised Controlled

IntroductionPerfluoroalkyl and polyfluoroalkyl substances (PFAS) are a diverse group of compounds that have been used in hundreds of industrial applications and consumer products including aqueous film-forming foam (AFFF) for many years. Multiple national and international health and environmental agencies have accepted that PFAS exposures are associated with numerous adverse health effects. Australian firefighters have been shown to have elevated levels of PFAS in their blood, specifically perfluorooctane sulfonic acid (PFOS) and perfluorohexane sulfonic acid (PFHxS), due to the historical use of AFFF. While PFAS concentrations decline over time once the source of exposure has been removed, their potential adverse health effects are such that it would be prudent to develop an intervention to lower levels at a faster rate than occurs via natural elimination rates.Methods and analysisThis is a randomised controlled trial of current and former Australian firefighters in the Metropolitan Fire Brigade/Fire Rescue Victoria, and contractors, with previous occupational exposure to PFAS and baseline elevated PFOS levels. The study is investigating whether whole blood donation every 12 weeks or plasma donation every 6 weeks will significantly reduce PFAS levels, compared with a control group. We have used covariate-adaptive randomisation to balance participants’ sex and blood PFAS levels between the three groups and would consider a 25% reduction in serum PFOS and PFHxS levels to be potentially clinically significant after 12 months of whole blood or plasma donation. A secondary analysis of health biomarkers is being made of changes between screening and week 52 in all three groups.Ethics and disseminationThis trial has been approved by Macquarie University Human Research Ethics Committee (reference number: 3855), final protocol V.2 dated 12 June 2019. Study results will be disseminated via peer-reviewed publications and presentations at conferences.Trial registration numberAustralian New Zealand Clinical Trials Registry (ACTRN12619000204145).

Sign in / Sign up

Export Citation Format

Share Document